Actemra, also known as tocilizumab, is a prescription medicine used to treat rheumatoid arthritis, juvenile idiopathic arthritis, and giant cell arteritis. Actemra works by blocking the effects of a protein called interleukin-6 (IL-6), which is involved in the inflammatory and immune responses that cause joint damage and systemwide inflammation in rheumatoid arthritis. Actemra is administered via injection under the skin or intravenously depending on the condition being treated. The global Actemra drug market is witnessing significant growth due to high prevalence of rheumatoid arthritis (RA) and other autoimmune diseases that Actemra is approved for treating.

The Actemra drug market is estimated to be valued at USD 3.796 Bn in 2024 and is expected to reach USD 6.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Key players operating in the Actemra drug market are Hoffmann-La Roche, Genentech, Novartis, Biogen, and Sanofi. Hoffmann-La Roche and Genentech currently dominate the market with their Actemra brand.

The rising prevalence of rheumatoid arthritis across the world is a major factor driving the growth of the Actemra Drug Market. According to latest statistics, around 24 million people worldwide suffer from RA with incidence rates expected to further increase over the coming years.

Technological advancements have enabled the development of improved and safer biologics for rheumatoid arthritis treatment. Compared to traditional disease-modifying anti-rheumatic drugs, biologics target specific proteins and molecules implicated in the pathogenesis of conditions like RA, reducing chances of side effects. This has boosted demand for drugs like Actemra.

Market Trends
Increasing R&D investments in novel RA treatment avenues: Efforts ongoing to develop more advanced IL-6 inhibitors with enhanced selectivity and specificity over Actemra. Drugs targeting other disease pathways also in pipeline.

Growing focus on biosimilars: With Actemra losing exclusivity in coming years, biosimilar competition expected to further drive down prices, improving accessibility in underserved regions.

Market Opportunities
Continued patent expirations of major biologics: Successful commercialization of an affordable Actemra biosimilar provides scope to capture market share vacated by expensive versions losing patents.

Unmet need in emerging nations: Despite rising need for advanced RA care in developing Asia Pacific and Latin America, availability and affordability remain significant issues. Biosimilars offer opportunity.

Impact of COVID-19 on Actemra Drug Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Actemra drug market globally. In the pre-COVID era, the market was growing at a steady pace owing to the increasing prevalence of rheumatoid arthritis and approval for new indications. However, during the COVID-19 outbreak, there was a surge in demand for Actemra since it was identified as a potential treatment for cytokine storm, a severe immune response, in critically ill COVID-19 patients. Several clinical trials were initiated to evaluate the drug's efficacy against COVID-19 associated complications.

As a result, the sales of Actemra grew exponentially during 2020 and 2021. The drugmaker Hoffmann-La Roche scaled up its production capacity to meet the rising demand from hospitals and healthcare systems. Some countries faced shortages initially due to supply constraints. However, with timely regulatory interventions and strategic production management, supply soon aligned with demand. The pandemic accelerated Actemra's clinical development and uptake remarkably.

Going forward, while the COVID-19 cases are receding in most parts of the world post widespread vaccination, medical experts fear recurrent spikes in infections due to emerging variants. This uncertain scenario may continue to support Actemra's off-label usage for COVID-19 management. Besides, the drug is still approved and prescribed for its original rheumatological indications. So full market recovery is expected in the coming years. Drugmakers plan to invest further in clinical evidence generation and portfolio expansion to tap new opportunities opened up during the pandemic period.

Geographical regions where Actemra Drug Market value is concentrated
The Actemra drug market value is highly concentrated in developed regions like North America, Europe, and Asia Pacific. Within North America, the United States represents the most lucrative market owing to the large patient pool of rheumatoid arthritis, favorable reimbursement policies, and greater affordability compared to developed Asian countries. In Europe, countries like Germany, France, Italy, Spain, and the United Kingdom together account for a major share of the regional market. Similarly, nations such as Japan, China, India, South Korea, Australia, among others contributed significantly to the Asia Pacific regional market.

Fastest growing region for Actemra Drug Market
Asia Pacific region is poised to witness the fastest growth in the global Actemra drug market during the forecast period. This is attributed to factors like rising healthcare expenditure, growing incidences of autoimmune disorders, increasing medical tourism, expansion of local pharmaceutical companies, and favorable regulations around innovative biologics. Furthermore, emerging economies in Asia Pacific are expected to supplement market expansion through their large patient bases and improving access to novel biologic treatment options such as Actemra. Overall, Asia Pacific presents extensive untapped opportunities for Actemra drug market players due to its immense population and ongoing developments in regional healthcare infrastructure and research landscape.

Get more insights on: Actemra Drug Market

Get this Report in Japanese Language: アクテムラ医薬品市場

Get this Report in Korean Language: 액템라 약물 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)